CAR T-Cell Therapy in Multiple Myeloma: Clinical Data and Patient Selection

A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.

Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.